

## REMARKS

In an Office Action mailed March 7, 2008, claims 1 – 28 are pending and all claims stand rejected. Claim 28 has been cancelled from the present application. Claims 1 – 27 have been amended for clarification, correction of typographical errors, grammatical errors, spelling errors and in order to conform to US format.

Claims 29 - 31 have been added. Support for new claims 29 – 31 may be found in the specification at pages 2 and 7. Claims 1 – 27 and 29 - 31 are currently pending.

The abstract has been placed on a separate sheet of paper according to U.S. practice.

### Claim Objections

Claim 26 is objected to because of informalities. Claim 26 has been amended to correct the informality.

### 35 U.S.C. § 112, second paragraph

Claim 1 was amended for clarification.

Formula 1 in claims 1 and 26 has been set forth.

Formulas 1 and 3 in claim 26 have been set forth.

Claim 28 has been cancelled from the present application. Therefore, the rejection is moot as to claim 28.

Applicants respectfully request the withdrawal of the rejection of claims 1 - 27 under 35 U.S.C. § 112, second paragraph.

### 35 U.S.C. § 101

Claim 28 has been cancelled from the present application. Therefore, the rejection is moot as to claim 28.

Attorney Docket No. PLP479USw  
Application No. 10/534,261  
Amendment Under 37 C.F.R §1.111


It is respectfully submitted that the present application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

The Commissioner is hereby authorized to charge such fees and any other fees required or credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,

Dated: June 5, 2008

GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: 919-483-2192  
Fax: 919-483-7988

  
Karen L. Prus

Attorney for Applicant  
Reg. No. 39,337